SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four key states: California, Nevada, Oregon, and Hawaii. These states represent over 290 ambulatory surgery centers (ASCs) where cataract and other ocular surgeries are performed, including California which has the most ASCs dedicated to ocular surgery in the country.
Imprimis currently provides two proprietary compounded antibiotic and steroid formulations available in single, injectable intraocular doses administered during ocular surgery. The first formulation contains triamcinolone acetonide and moxifloxacin hydrochloride (Tri-Moxi), and a second variation includes the added antibiotic vancomycin (Tri-Moxi-Vanc). These medications are available with a physician’s prescription for individual patients and have been administered in over 40,000 ophthalmic procedures, primarily cataract surgeries.
Injectable intraocular drugs can simplify the post-operative process and provide safeguards against bacterial infection and inflammation. They reduce dependence on expensive, topical post-operative eye drop therapy resulting in a significant decrease in the overall cost of the surgical procedure. With Dropless formulations, patients may no longer need to administer multiple topical drops daily thereby largely eliminating patient non-compliance issues. Dropless Therapy has tremendous potential benefit to patients, particularly the physically and economically disadvantaged, along with caregivers, surgeons, staff, and the healthcare system alike.
To order Dropless formulations in California, Nevada, Oregon, or Hawaii, ophthalmologists or their representatives should call (858) 704-4040 or visit www.GoDropless.com to reach Imprimis Pharmaceuticals regional associates for account setup and ordering.
ABOUT GO DROPLESS
Imprimis has been making its ophthalmic sterile compound formulations available since the launch of its Go Dropless! campaign in April 2014. Since launch, more than 175 ophthalmologists have begun prescribing Imprimis’ formulations for their patients. At leading ophthalmology meetings, physicians have reported a greater than 90 percent success rate in eliminating the use of post-operative eye drops for cataract surgery patients. Dropless Therapy has garnered extensive national media attention, with over 40 trade media references published in 2014. Given its significant potential cost savings to the healthcare system, Imprimis has begun working with both public and private payors on possible reimbursement policies.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies, which include formulations in ophthalmology and urology. For more information about Imprimis, please visit the company’s corporate website at www.ImprimisPharma.com; ophthalmology business website at www.GoDropless.com; and urology business website at www.DefeatIC.com.
SAFE HARBOR
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to the possibility that the closing of the acquisition of Park may be delayed or may not occur; difficulties with the integration process or the realization of the expected benefits of the Park acquisition; Imprimis’ ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to compounding pharmacy operations; Imprimis’ ability to expand its compounding pharmacy operations, through additional compounding pharmacies, outsourcing facilities or otherwise, to reach nationwide distribution capabilities; Park’s ability to maintain or improve its business, including its profitability and quality standards; Imprimis’ ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; Imprimis’ ability to obtain intellectual property protection for its assets; Imprimis’ ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry generally; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s website at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Sales/Marketing Contact:
Etani Susman
esusman@imprimispharma.com
858.704.4494
Media Contact:
Deb Holliday
deb@pascalecommunications.com
412.877.4519
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-expands-proprietary-ophthalmic-formulations-to-four-key-western-states-300003959.html
SOURCE Imprimis Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
